Embed Size (px)
Transcript of C:\Whitney Docs\Healthreformandkeyhealthindustries
- 1. Health Reform and Key Health Industries: Implications, Challenges, and OpportunitiesMay 28, 2010
Kip Piper, MA, FACHE
2. Briefing Agenda
Hospitals and Health Systems
Health Insurers / Health Plans
Physicians and Clinics
Pharma and Biotech Industries
Medical Technology Industry
3. Hospitals and Health Systems
- Substantial decrease in bad debt as Medicaid and new subsidized Exchange plans expand coverage to ~32 million (net).
5. Around 2014-2018, significant increase in volume, particularly for elective procedures.Pent-up demand from newly insured. 6. Short-term bargaining power as insurers try to secure adequate capacity for 32 million new enrollees. 7. New payment methods create major opportunities Bundled payment, global fees, Accountable Care Organizations. 8. Tapping $10 billion for Medicare / Medicaid demonstrations.New Center for Medicare and Medicaid Innovation (CMI) at CMS. 9. Protection against increased competition from physician-owned hospitals.4
- About $155 billion in payment cuts Lower cost updates in Medicare, reduction in Medicare and Medicaid payments for uncompensated care.
11. Major increase in Medicaid volume.Medicaid is typically lowest payor. 12. Increasing financial pressure to move away from traditional revenue optimization model to operational efficiency. 13. Major new, expanding compliance risks.More audits, etc. 14. Coverage expansion raises questions about need uncompensated care payments and other special Medicaid financing. 15. Public hospitals may lose patient volume as newly insured trade-up to newer, better facilities. 16. Lower payments from commercial and Medicaid plans likely in long range.Insurers far less likely to cross subsidize Medicare and Medicaid.5
- Medicare and Medicaid margins will remain tight.More budget-driven payment cuts highly likely.
18. Rate pressure from health insurers, as the insurers face tougher competition, lower profits and increase market power via consolidation, enrollment. 19. About 42% of uninsured will remain uninsured.Not solution to costs of unauthorized immigrants. 20. Significant consolidation likely.Of hospitals, health systems, physician group practices.Hospitals buying or partnering with physician groups. 21. Significant pressure on increasing operating efficiency, reducing readmissions and infection rates. 22. Heavy interest in demos, new payment methods, and delivery system reforms.Major advantages to early adopters. 6
23. Health Insurers / Health Plans
24. Health Insurers:Opportunities
- Medicaid expansion to ~16 million enrollees:
25. 25% increase in Medicaid market, 50%+ in many states. 26. Likely 75%+ will enroll in Medicaid health plans under contract with states. 27. New Health Insurance Exchange market, with ~26 million enrollees (16 million newly covered). 28. New opportunities in specialized markets: 29. $300 billion+ Medicare-Medicaid dual eligibles market 30. $170 billion long-term care market 31. Federal support to create co-op health plans $6 billion. 32. New $5 billion temporary federal high-risk pool. 33. Savings potential from comparative effectiveness research, new provider payment models, biosimilars, and electronic health records. 34. More uniform insurance regulatory framework across US. 8
35. HEALTH INSURERS:Challenges
- Significant new federal and state regulations.Added complexity, major compliance risks.
36. New federal taxes $70 billion. 37. Requirement on Medical Loss Ratios mandate limiting amount of premiums available for marketing, administration, profit.Minimum MLR of 85% or 80%. 38. In Medicare Advantage market, lower payments and fewer enrollees or slow growth. 39. Traditionally profitably individual and small group markets will shrink dramatically as Exchanges begin.Employer-sponsored market will also shrink.At least 10 million, likely far more due to crowd out. 40. Newly insured likely challenging to serve. 41. Covering patients with pre-existing conditions will be costly. 42. New provider payment methods, delivery reforms favor providers over plans.9
43. HEALTH INSURERS:Implications
- Overall net increase in premium revenue due to 32 million new enrollees in Medicaid and subsidized Exchange plans.
44. Significant pressure on profit margins due to combination of factors:floor on medical spending, Medicare Advantage cuts, loss of profitable segments. 45. With pressure on profit margins and need to grow revenue, insurers will consolidate and look for ways to grow in untapped markets (dual eligibles). 46. Federal and state government continue to grow as the dominate customer more need to understand, navigate, influence, comply with government. 10
47. Physicians and Clinics
48. PHYSICIANS AND CLINICS:Opportunities
- In Medicare, 10% bonus payment to primary care physicians from 2011 through 2015.
49. In Medicaid, Medicaid primary care physicians paid minimum of 100% of Medicare rates in 2013 and 2014. 50. More federal funding for community health centers: $10 billion. 51. New payment methods and delivery reforms empower high-performing providers.Major opportunities via new pilots and demos in Medicare and Medicaid. 52. Easier access to patient records, easier to coordinate and track care.12
53. PHYSICIANS AND CLINICS:Challenges
- Increased demand for services.Primary care capacity inadequate to handle 32 million newly insured.
54. Unless Congress acts, Medicare will cut physician rates by 21.3% on June 1. 55. Cost of another extension of current rates will cost about $98 billion or more.Permanent fix to Medicare doc rate problem will cost minimum of $275 billion. 56. Implementation of EHRs, meaningful use, and new workflow. 57. Pressure to follow evidenced-based medicine, improve safety and efficiency. 58. New Value Index will adjust Medicare payments on the physicians relative cost and quality. 59. Continued increase in quality measurement and reporting, with payment penalties for not reporting.13
60. PHYSICIANS AND CLINICS:Implications
- Short-term, increased bargaining power as insurers seek capacity to serve newly insured.
61. Government programs will continue to grow as dominate payor. 62. Low rates.Medicare rate problem continue for years.Payment rates unlikely to keep up with costs.Increases for primary care may come from cuts to specialty rates. 63. Physician practices will see increased competition from health systems, retail health clinics, federally subsidized community health centers. 64. Small practices will become increasingly difficult to operate, financially unviable.Pressure to consolidate and partner. 65. Continued decrease in market influence, autonomy. 14
66. Pharma / Biotech Industry
67. PHARMA & BIOTECH:Opportunities
- Newly insured will likely increase demand for drugs and biologics.Lower demand for patient assistance programs.
68. New pathway for biosimilars.Opportunity for some manufacturers, hit for others. 69. New policies promoting prevention, chronic care management, medication management. 70. Center for Medicare and Medicaid Innovation, demos, pilots opportunities to influence, partner. 71. Increased use of HIT may increase compliance and thus volume of certain drugs.New data may decrease cost of clinical trials. 72. Market opportunities for makers of value drugs drugs adding value, not merely novel.16
73. PHARMA & BIOTECH:Challenges
- Lower profit margins in two biggest US markets Medicare and Medicaid:
74. Mandatory 50% discounts in Medicare donut hole $32 billion cost. 75. Minimum Medicaid rebate of 23%, up from 15%. 76. Mandatory rebates extended to Medicaid health plans 77. 25% increase in Medicaid market. 78. New federal fees on manufacturers $27 billion over 10 years.Tighter profits. 79. Comparative effectiveness research! 80. New payment methods will change roles, incentives for physicians and hospitals. 81. New pathway for biosimilars.Long-range hit to brand biologics. 82. Increased compliance risks.17
83. PHARMA & BIOTECH:Implications
- Increase in volume in 2014-2019 from newly insured, patient protections.
84. Lower profit margins for many brand products. 85. Higher proportion of business from public programs with all the associated implications. 86. Significant pressure from comparative effectiveness research and value-based benefit designs.Must incorporate into clinical trial design, market strategy. 87. Biosimilars will have impact but will roll out over several years.Payors will be eager to use biosimilars. 88. Imperative to leverage, adapt to new policy environment payment reforms, delivery reforms. 89. States will increase as legislative battle ground. 90. Extension of Medicaid-style rebates to Medicare Part D likely inevitable.18
91. Medical Technology Industry
92. MEDICAL TECHNOLOGY:Opportunities
- Like other industries, a volume increase is